IBDEI10Y ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16473,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16473,1,3,0)
 ;;=3^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,16473,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,16473,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,16474,0)
 ;;=C82.09^^88^879^65
 ;;^UTILITY(U,$J,358.3,16474,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16474,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,16474,1,4,0)
 ;;=4^C82.09
 ;;^UTILITY(U,$J,358.3,16474,2)
 ;;=^5001470
 ;;^UTILITY(U,$J,358.3,16475,0)
 ;;=C82.00^^88^879^66
 ;;^UTILITY(U,$J,358.3,16475,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16475,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Unspec Site
 ;;^UTILITY(U,$J,358.3,16475,1,4,0)
 ;;=4^C82.00
 ;;^UTILITY(U,$J,358.3,16475,2)
 ;;=^5001461
 ;;^UTILITY(U,$J,358.3,16476,0)
 ;;=C82.19^^88^879^67
 ;;^UTILITY(U,$J,358.3,16476,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16476,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,16476,1,4,0)
 ;;=4^C82.19
 ;;^UTILITY(U,$J,358.3,16476,2)
 ;;=^5001480
 ;;^UTILITY(U,$J,358.3,16477,0)
 ;;=C82.10^^88^879^68
 ;;^UTILITY(U,$J,358.3,16477,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16477,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Unspec Site
 ;;^UTILITY(U,$J,358.3,16477,1,4,0)
 ;;=4^C82.10
 ;;^UTILITY(U,$J,358.3,16477,2)
 ;;=^5001471
 ;;^UTILITY(U,$J,358.3,16478,0)
 ;;=C82.29^^88^879^69
 ;;^UTILITY(U,$J,358.3,16478,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16478,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,16478,1,4,0)
 ;;=4^C82.29
 ;;^UTILITY(U,$J,358.3,16478,2)
 ;;=^5001490
 ;;^UTILITY(U,$J,358.3,16479,0)
 ;;=C82.20^^88^879^70
 ;;^UTILITY(U,$J,358.3,16479,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16479,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Unspec Site
 ;;^UTILITY(U,$J,358.3,16479,1,4,0)
 ;;=4^C82.20
 ;;^UTILITY(U,$J,358.3,16479,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,16480,0)
 ;;=C82.39^^88^879^71
 ;;^UTILITY(U,$J,358.3,16480,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16480,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,16480,1,4,0)
 ;;=4^C82.39
 ;;^UTILITY(U,$J,358.3,16480,2)
 ;;=^5001500
 ;;^UTILITY(U,$J,358.3,16481,0)
 ;;=C82.30^^88^879^72
 ;;^UTILITY(U,$J,358.3,16481,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16481,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
 ;;^UTILITY(U,$J,358.3,16481,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,16481,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,16482,0)
 ;;=C82.49^^88^879^73
 ;;^UTILITY(U,$J,358.3,16482,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16482,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,16482,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,16482,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,16483,0)
 ;;=C82.40^^88^879^74
 ;;^UTILITY(U,$J,358.3,16483,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16483,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,16483,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,16483,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,16484,0)
 ;;=C82.99^^88^879^75
 ;;^UTILITY(U,$J,358.3,16484,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16484,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,16484,1,4,0)
 ;;=4^C82.99
